Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

78.42 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 77,306
Open 78.42
Bid (Size) 78.49 (10)
Ask (Size) 78.57 (14)
Prev. Close 78.42
Today's Range 78.42 - 78.42
52wk Range 60.47 - 80.86
Shares Outstanding N/A
Dividend Yield 1.19%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a... 
Via Benzinga
Exposures COVID-19
AstraZeneca's Combination Cancer Drug For Advanced Breast Cancer Study Flunks Late-Stage Trial
AstraZeneca announced that the CAPItello-290 Phase 3 trial for Truqap (capivasertib) combined with paclitaxel in advanced or metastatic triple-negative breast cancer did not meet primary endpoints for... 
Via Benzinga

Performance

YTD
+14.65%
+14.65%
1 Month
+1.70%
+1.70%
3 Month
+19.31%
+19.31%
6 Month
+19.22%
+19.22%
1 Year
+6.04%
+6.04%

More News

Read More
What's Going On With Small-Cap Cancer Focused Nurix Therapeutics On Monday?
Via Benzinga
IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer
From AstraZeneca
Via Business Wire
Here's How Much You Would Have Made Owning AstraZeneca Stock In The Last 5 Years
Via Benzinga
FDA Approves AstraZeneca Treatment For Advanced Endometrial Cancer
Via Benzinga
Exposures Product Safety
3 Best Stocks to Buy From the Fantastic 5
Via InvestorPlace
AstraZeneca Says Calquence/Chemo Combo Data Shows Additional 16.8 Months Without Disease Progression In Patients With Certain Type Of Blood Cancer
Via Benzinga
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
From AstraZeneca
Via Business Wire
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
Via Investor's Business Daily
FARXIGA approved in the US for the treatment of pediatric type-2 diabetes
From AstraZeneca
Via Business Wire
Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
Via Investor's Business Daily
3 Crazy Good Stocks to Buy With $500 Right Now
Via InvestorPlace
Healthcare And Biotech Investing: Breakthroughs In The Treatment Of Cancer At ASCO
Via Talk Markets
Meet The International Megacaps That 'Match Or Surpass' Magnificent Seven Stocks
Via Investor's Business Daily
TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
From AstraZeneca
Via Business Wire
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
Via Talk Markets
The No-Brainer Buys: 3 Stocks That Are Absolute Must-Owns Right Now
Via InvestorPlace
Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate
Via InvestorPlace
Large Cap BIopharmaceuticals Overview
Via Talk Markets
Topics Stocks
Exposures US Equities
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Via The Motley Fool
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
From AstraZeneca
Via Business Wire
Stocks Seeing Relentless Buying Pressure; Bonds Are Not
Via Talk Markets
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
From AstraZeneca
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy
From AstraZeneca
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.